Please login to the form below
biosimilars
This page shows the latest biosimilars news and features for those working in and with pharma, biotech and healthcare.
Roche preps new Kadcyla filings after phase 3 trial win
That will help support the $10bn-plus franchise as Herceptin faces the threat of biosimilar competition in some European markets, including the UK.
Latest news
-
Encouraging data for Roche flu drug ahead of FDA decision
Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.
-
Novartis sells off part of Sandoz portfolio
Novartis sells off part of Sandoz portfolio. Swiss pharma giant will retain biosimilars. ... Francis adds: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics,
-
Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more
Herceptin biosimilars can’t make Perjeta cost effective, says NICE. NICE has once again rejected Roche’s HER2-positive breast cancer drug Perjeta for treating patients after surgery in those who ... The Institute had already rejected it in this
-
ABPI hits out at ‘punitive’ UK medicines pricing plan
The consultation also contain plans to bring biosimilar products into the statutory scheme – an idea also vehemently opposed by representatives of the sector. ... Warwick Smith went as far as to say the proposals might deter some companies from
-
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar
Daily Brief: European approvals for BMS' Opdivo, Aegerion's lipodystrophy treatment, Pfizer's biosimilar. ... Will Pfizer spark price war with its Herceptin biosimilar? Eclipsed, but still growing: Opdivo approved in new melanoma setting.
More from news
Approximately 129 fully matching, plus 302 partially matching documents found.
Latest Intelligence
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
In recent years, biosimilars (highly similar copies of biologic medicines) have taken large shares of many markets. ... They come with a reduced price, which could offer a very substantial point of differentiation, but then so do many other biosimilars
-
Mylan sees the UK paving the way for an insulin game changer
biosimilars could take up a portion of that, then it could create 15bn savings in Europe, if not more, ”. said Brault. “It is about increasing access. Bringing a biosimilar insulin to ... Brault added that the biosimilar launch would represent an
-
30 Women Leaders in UK Healthcare
Bringing people together to make things happen across organisational lines, Angela is leading projects to exploit real-world evidence, adaptive trials, accelerate the uptake of biosimilars and assist in Greater
-
Uncertainty, austerity and Brexit
Alongside this, rumours that NHS England was planning to include biosimilars on the Accelerated Access Pathway, the flagship policy intervention designed to speed up the use of innovative products, would amount
-
The good, the bad and the ugly
These declines are driven by the patent expiry of Enbrel and subsequent brand erosion caused by the launch of biosimilars, ”says Annis. ... The rise of biosimilars is likely to present the main challenge to immunology products in 2018, particularly in
More from intelligence
Approximately 11 fully matching, plus 50 partially matching documents found.
Latest appointments
-
Ashfield, Health Unlimited and Ashley Communications adds to their teams
Van Weperen was most recently at diabetes giant Novo Nordisk, where he worked on delivering insulin and GLP1 biosimilar defence strategies, leading Novo’s UK diabetes team.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
PharmaLex appoints Zabin Younes as associate director
She joins the group as an associate director and arrives from ERA Consulting - a biopharmaceutical consultancy based in the UK - where she picked up experience in the biosimilar development lifecycle. ... With experience spanning over 15 years,
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
-
Sandoz UK promotes Tim de Gavre to country head
Novartis’generics and biosimilar division Sandoz has appointed Tim de Gavre as its new country head for the UK. ... Our combined portfolio of small molecule generics and biosimilars makes a significant different to medicines costs, and helps the NHS
More from appointments
Approximately 1 fully matching, plus 14 partially matching documents found.
Latest from PMHub
-
Biosimilars: Getting the flock to market
The factor that drives the success of biosimilars is value. The biosimilar dividend is that more patients can get access to the high-value treatments they need. ... Luckily, the biosimilar path has already been trodden, so new agents can slipstream the
-
Webinar: What next for biosimilars?
Webinar: What next for biosimilars? Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST. ... Join market research consultants Laurent Chanroux and Richard Head for this complimentary webinar in which they will explore and compare biosimilars in RA and
-
Video: Global Biosimilars Market
Video: Global Biosimilars Market. Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch. ... It is predicted that
-
Tackling biosimilars – how to handle the threat to Pharma brands
Strategy Consultant Mark Assenti talks through three key points for developing a strategy to tackle biosimilars. ... Therefore, while the biosimilar drugs may be very similar, they will never be identical.
-
Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?
Free Thinking: Are biosimilars the answer to the rising cost of RA treatment? ... With Enbrel biosimilar Benepali about to launch across EU, we ask what’ s next for RA?
More from PMHub
Approximately 17 fully matching, plus 29 partially matching documents found.
Featured jobs
- Experienced Editor, London, Medical Communications
-
Competitive package
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
-
Senior Account Manager - Med Comms
-
Highly Competitive Salary &Benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Associate Medical Director
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
-
Account Director - Digital
-
Great salary and benefits
-
Account Director
-
Negotiable
-
Scientific Director
-
Highly Competitive Salary &Benefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
- Account Director – Global Healthcare PR
-
Salary TBC
- Account Manager, Healthcare Advertising
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
-
Scientific Team Lead
-
Competitive Salary
Subscribe to our email news alerts
- AcelRX’s potent opioid tablets set to win FDA backing for pain relief
- New leader at Medivir after setbacks
- Roche preps new Kadcyla filings after phase 3 trial win
- Porterhouse Medical Group boosts its scientific services team with two new appointments
- Redefining communications excellence
- AstraZeneca: building a new ‘open innovation’ pharma company
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...
Latest intelligence
- Redefining communications excellence
- How to be heard in today’s multichannel, multistakeholder, multimedia world...
- AstraZeneca: building a new ‘open innovation’ pharma company
- The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
- In conversation with Pfizer’s Erik Nordkamp
- Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...
Quick links
Infographics
